HL Financial Services LLC boosted its position in ABIOMED, Inc. (NASDAQ:ABMD) by 8.1% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,705 shares of the medical equipment provider’s stock after buying an additional 2,236 shares during the period. HL Financial Services LLC owned approximately 0.07% of ABIOMED worth $4,257,000 at the end of the most recent reporting period.
Other institutional investors have also recently bought and sold shares of the company. Dimensional Fund Advisors LP raised its position in ABIOMED by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 132,006 shares of the medical equipment provider’s stock worth $14,875,000 after buying an additional 4,990 shares during the last quarter. William Blair Investment Management LLC raised its position in ABIOMED by 8.9% in the first quarter. William Blair Investment Management LLC now owns 1,121,017 shares of the medical equipment provider’s stock worth $140,351,000 after buying an additional 91,651 shares during the last quarter. World Asset Management Inc raised its position in ABIOMED by 17.0% in the first quarter. World Asset Management Inc now owns 2,844 shares of the medical equipment provider’s stock worth $356,000 after buying an additional 413 shares during the last quarter. Fox Run Management L.L.C. purchased a new position in ABIOMED during the second quarter worth $588,000. Finally, Creative Planning raised its position in ABIOMED by 16.4% in the first quarter. Creative Planning now owns 916 shares of the medical equipment provider’s stock worth $115,000 after buying an additional 129 shares during the last quarter. Institutional investors and hedge funds own 91.09% of the company’s stock.
ABIOMED, Inc. (NASDAQ ABMD) opened at 152.14 on Friday. ABIOMED, Inc. has a 52-week low of $95.14 and a 52-week high of $157.41. The company has a market cap of $6.68 billion, a price-to-earnings ratio of 88.97 and a beta of 0.20. The firm’s 50-day moving average is $147.23 and its 200 day moving average is $132.32.
ABIOMED (NASDAQ:ABMD) last announced its earnings results on Thursday, July 27th. The medical equipment provider reported $0.45 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.42 by $0.03. ABIOMED had a net margin of 16.13% and a return on equity of 13.03%. The company had revenue of $132.47 million for the quarter, compared to analysts’ expectations of $130.83 million. During the same quarter in the previous year, the company posted $0.29 EPS. The firm’s quarterly revenue was up 28.6% on a year-over-year basis. On average, equities research analysts predict that ABIOMED, Inc. will post $2.24 EPS for the current fiscal year.
A number of equities analysts recently weighed in on the stock. Morgan Stanley restated an “equal weight” rating and set a $140.00 target price (up previously from $135.00) on shares of ABIOMED in a research report on Monday, July 10th. William Blair restated an “outperform” rating on shares of ABIOMED in a research report on Thursday, June 8th. Zacks Investment Research lowered shares of ABIOMED from a “buy” rating to a “hold” rating in a research report on Wednesday, July 5th. Piper Jaffray Companies set a $145.00 target price on shares of ABIOMED in a research report on Tuesday, July 4th. Finally, Jefferies Group LLC upped their target price on shares of ABIOMED from $165.00 to $175.00 and gave the stock a “buy” rating in a research report on Friday, August 4th. Two equities research analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Buy” and an average price target of $158.29.
In other ABIOMED news, COO David M. Weber sold 16,500 shares of ABIOMED stock in a transaction on Monday, July 31st. The shares were sold at an average price of $147.63, for a total transaction of $2,435,895.00. Following the sale, the chief operating officer now owns 125,122 shares of the company’s stock, valued at approximately $18,471,760.86. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Paul Thomas sold 10,000 shares of ABIOMED stock in a transaction on Tuesday, August 15th. The stock was sold at an average price of $154.71, for a total transaction of $1,547,100.00. Following the sale, the director now directly owns 12,172 shares in the company, valued at approximately $1,883,130.12. The disclosure for this sale can be found here. Insiders own 7.00% of the company’s stock.
ABIOMED, Inc is a provider of temporary percutaneous mechanical circulatory support devices. The Company offers care to heart failure patients. The Company operates in the segment of the research, development and sale of medical devices to assist or replace the pumping function of the failing heart. The Company develops, manufactures and markets products that are designed to enable the heart to rest, heal and recover by improving blood flow to the coronary arteries and end-organs and/or temporarily performing the pumping function of the heart.
Receive News & Ratings for ABIOMED Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ABIOMED Inc. and related companies with MarketBeat.com's FREE daily email newsletter.